CN104336596A - Medicine composition capable of lowering blood lipid and preparation method thereof - Google Patents
Medicine composition capable of lowering blood lipid and preparation method thereof Download PDFInfo
- Publication number
- CN104336596A CN104336596A CN201310331251.3A CN201310331251A CN104336596A CN 104336596 A CN104336596 A CN 104336596A CN 201310331251 A CN201310331251 A CN 201310331251A CN 104336596 A CN104336596 A CN 104336596A
- Authority
- CN
- China
- Prior art keywords
- parts
- root
- kudzu vine
- blood lipid
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 29
- 239000008280 blood Substances 0.000 title claims abstract description 29
- 150000002632 lipids Chemical class 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title claims abstract 5
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000000203 mixture Substances 0.000 title abstract description 5
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 20
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 20
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 14
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 14
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 14
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract 5
- 241000233838 Commelina Species 0.000 claims description 13
- 241000218628 Ginkgo Species 0.000 claims description 13
- 240000007164 Salvia officinalis Species 0.000 claims description 13
- 235000005412 red sage Nutrition 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000000638 solvent extraction Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000012054 meals Nutrition 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000011122 softwood Substances 0.000 claims description 3
- 235000020985 whole grains Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 15
- 235000013291 Alisma plantago aquatica Nutrition 0.000 abstract 1
- 240000004615 Alisma plantago-aquatica Species 0.000 abstract 1
- 241000233839 Commelina communis Species 0.000 abstract 1
- 244000084791 Curculigo orchioides Species 0.000 abstract 1
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 208000024780 Urticaria Diseases 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 28
- 238000012360 testing method Methods 0.000 description 26
- 241000700159 Rattus Species 0.000 description 25
- 108010023302 HDL Cholesterol Proteins 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 208000031226 Hyperlipidaemia Diseases 0.000 description 10
- 241001065361 Gynostemma Species 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 238000007689 inspection Methods 0.000 description 7
- 230000002402 anti-lipaemic effect Effects 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010067482 No adverse event Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 235000019082 Osmanthus Nutrition 0.000 description 2
- 241000333181 Osmanthus Species 0.000 description 2
- 241000238370 Sepia Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000007887 hard shell capsule Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 240000007509 Phytolacca dioica Species 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine composition capable of lowering blood lipid. The medicine composition comprises the following raw medicines in parts by weight: 50 parts of commelina communis, 50 parts of Curculigo orchioides, 50 parts of Salvia miltiorrhiza, 50 parts of ginkgo leaves, 35 parts of Alisma plantago-aquatica, 35 parts of Kudzuvine root, 10 parts of hives, and 20 parts of gynostemma pentaphyllum. The low, middle and high dosage groups of the medicine composition all can effectively lower the blood lipid in the human body, and are safe to use and have remarkable curative effect.
Description
Technical field
The present invention relates to pharmaceutical composition of a kind of reducing blood lipid and preparation method thereof, belong to field of health care food.
Background technology
Along with the raising of people's lives, the expanding day of people with hyperlipidemia, and the diabetes caused by high fat of blood, blood circulation system disease is increasing to human health risk.Along with the market demand, the health food with auxiliary antilipemic also increases gradually, but works mainly with the form of one-component greatly, and act synergistically poor, effect is not obvious, still can not meet the needs in market.
Summary of the invention
Object of the present invention is just to provide a kind of pharmaceutical composition of more efficiently auxiliary antilipemic effect.
The compositions of reducing blood lipid of the present invention forms primarily of the Chinese medicine of following weight portion: dayflower 30-70 part, thizoma curculiginis 30-70 part, red sage root 30-70 part, ginkgo leaf 30-70 part, rhizoma alismatis 20-50 part, root of kudzu vine 20-50 part, honeycomb 5-15 part, gynostemma pentaphylla 10-30 part.
Preferably, each Chinese medicine and weight portion thereof are respectively: dayflower 40-60 part, thizoma curculiginis 40-60 part, red sage root 40-60 part, ginkgo leaf 40-60 part, rhizoma alismatis 30-40 part, root of kudzu vine 30-40 part, honeycomb 8-12 part, gynostemma pentaphylla 15-25 part.
More preferably, each Chinese medicine and weight portion thereof are respectively: dayflower 50 parts, thizoma curculiginis 50 parts, the red sage root 50 parts, ginkgo leaf 50 parts, rhizoma alismatis 35 parts, the root of kudzu vine 35 parts, 10 parts, honeycomb, gynostemma pentaphylla 20 parts.
The present invention also provides the preparation method of above-mentioned Antilipidemic pharmaceutical compositions:
1) by the root of kudzu vine pulverize, cross 100 mesh sieves, every prescription collect 50g fine powder (
60co radiation, dosage < 5ky), all the other meal are for extraction.
2) red sage root, ginkgo leaf, rhizoma alismatis, the root of kudzu vine, gynostemma pentaphylla, dayflower, thizoma curculiginis, honeycomb 80% alcohol reflux extract 2 times, first time adds 10 times amount solvent extraction 2h, second time adds 8 times amount solvent extraction 1.5h, merge twice filtrate (the another device of the dregs of a decoction is preserved), decompression (-0.065 ~-0.075Mpa; 60 DEG C) concentrated, reclaim ethanolic solution and be concentrated into relative density 1.32 ~ 1.35(60 DEG C) medicinal extract 1 for subsequent use.
3) the above-mentioned dregs of a decoction add 8 times amount soak by water 1 time, and the time, 1.5h considered, filtrate decompression (-0.065 ~-0.075Mpa; 60 DEG C) to be concentrated into relative density be 1.32 ~ 1.35(60 DEG C) medicinal extract 2 for subsequent use.
4) medicinal extract 1 and medicinal extract 2, root of kudzu vine fine powder are mixed, dry, pulverize 80 mesh sieves with less than 65 DEG C reduce pressure (-0.075 ~-0.085Mpa).
5) above-mentioned fine powder 85% appropriate amount of ethanol makes softwood, 20 mesh sieves granulate less than 60 DEG C dry, the whole grain of 16 mesh sieve, loads No. 0 capsule and get final product.
Beneficial effect
The traditional Chinese medical science thinks that hyperlipidemia genus " this void table is real " is demonstrate,proved, and with the internal resistance of the phlegm stasis of blood for mark, the dirty functional disturbance of liver,spleen,kidney three is originally.
Rhizoma alismatis, the clearing heat and detoxicating soothing the liver clearing gallbladder of dayflower, to help the transporting of taste; Gynostemma pentaphylla, thizoma curculiginis tonifying middle-Jiao and Qi, invigorating the spleen production of sperm, with Zhi Qiben; Ginkgo, the root of kudzu vine, the red sage root, honeycomb eliminates the phlegm and stomach promotes the production of body fluid, resolving turbidity and eliminating dampness control altogether its mark.
Detailed description of the invention
Following examples for illustration of the present invention, but are not used for limiting the scope of the invention.
Embodiment 1
Prescription forms:
Dayflower 60 parts, thizoma curculiginis 40 parts, the red sage root 60 parts, ginkgo leaf 40 parts, rhizoma alismatis 40 parts, the root of kudzu vine 30 parts, 12 parts, honeycomb, gynostemma pentaphylla 15 parts.
The preparation method of the pharmaceutical composition of reducing blood lipid of the present invention:
1) by the root of kudzu vine pulverize, cross 100 mesh sieves, every prescription collect 50g fine powder (
60co radiation, dosage < 5ky), all the other meal are for extraction.
2) red sage root, ginkgo leaf, rhizoma alismatis, the root of kudzu vine, gynostemma pentaphylla, dayflower, thizoma curculiginis, honeycomb 80% alcohol reflux extract 2 times, first time adds 10 times amount solvent extraction 2h, second time adds 8 times amount solvent extraction 1.5h, merge twice filtrate (the another device of the dregs of a decoction is preserved), decompression (-0.065 ~-0.075Mpa; 60 DEG C) concentrated, reclaim ethanolic solution and be concentrated into relative density 1.32 ~ 1.35(60 DEG C) medicinal extract 1 for subsequent use.
3) the above-mentioned dregs of a decoction add 8 times amount soak by water 1 time, and the time, 1.5h considered, filtrate decompression (-0.065 ~-0.075Mpa; 60 DEG C) to be concentrated into relative density be 1.32 ~ 1.35(60 DEG C) medicinal extract 2 for subsequent use.
4) medicinal extract 1 and medicinal extract 2, root of kudzu vine fine powder are mixed, dry, pulverize 80 mesh sieves with less than 65 DEG C reduce pressure (-0.075 ~-0.085Mpa).
5) above-mentioned fine powder 85% appropriate amount of ethanol makes softwood, 20 mesh sieves granulate less than 60 DEG C dry, the whole grain of 16 mesh sieve, loads No. 0 capsule and get final product.
Embodiment 2
Prescription forms:
Dayflower 40 parts, thizoma curculiginis 60 parts, the red sage root 40 parts, ginkgo leaf 60 parts, rhizoma alismatis 30 parts, the root of kudzu vine 40 parts, 8 parts, honeycomb, gynostemma pentaphylla 25 parts.
The preparation method of the pharmaceutical composition of reducing blood lipid of the present invention is with embodiment 1
Embodiment 3
Prescription forms:
Dayflower 50 parts, thizoma curculiginis 50 parts, the red sage root 50 parts, ginkgo leaf 50 parts, rhizoma alismatis 35 parts, the root of kudzu vine 35 parts, 10 parts, honeycomb, gynostemma pentaphylla 20 parts.
The preparation method of the pharmaceutical composition of reducing blood lipid of the present invention is with embodiment 1
Embodiment 4
Health food hard shell capsules auxiliary lipid-lowering function Report on Animal of the present invention
1. materials and methods
1.1 samples and test liquid preparation: pharmaceutical composition medicine of the present invention, by Shaanxi, century-old healthy pharmaceutcal corporation, Ltd provides, and for content sepia capule size is 0.35g/ grain, human body recommends consumption for adult (everyone) every day 2 times, each 3, convert 35mg/kgBW by body weight 60kg.Room temperature preservation.Before experiment with 5% starch solution sample dispense become 17.5,35.0, the solution of 70.0mg/ml is for trying out.
1.2 experimental animals: male rat 60 in cleaning grade (II grade) Wistar selecting Guangxi medical pharmaceutical university Experimental Animal Center ［ approval number is osmanthus dynamic (2000) the 001st ］ to breed, body weight 207 ± 22.6g.This center experimental animal room quality certification number: dynamic No. 23003rd, the word of osmanthus doctor.Animal housing's temperature 22 ~ 25 DEG C, relative humidity 55 ~ 70%.
1.3 dosage choice and animal subject give mode: human body day per sample recommends consumption, 700,350 if, 175mg/kgBW(is equivalent to 20,10,5 times of human body recommended amounts respectively) 3 dosage groups, separately establish a basal feed control group and a high model control group (high fat group).Often organize 14 animals.Give test solution in per os mode, gavage amount is 1.0ml/100g BW.
1.4 key instruments and reagent:
Instrument: Hitachi KY2000 type semi-automatic biochemical analyzer, centrifuge, whirlpool are mixed device and water bath with thermostatic control etc.
Reagent: T-CHOL (TC), triglycerides (TG), HDL-C (HDL-C) kit (Zhongsheng Beikong Biological Science & Technology Co., Ltd. produces, and lot number is respectively 181091,222062,190161)
1.5 test methods: according to the auxiliary lipid-lowering function method of inspection in " health food inspection and assessment technical specification-2003 ", employing hyperlipoidemia method-preventative to given the test agent.Rat observes 5 days at the indoor nursing basal feed of SPF level zoopery, and the intraocular corner of the eyes gets hematometry every blood fat observation index normal value.According to TC level, adopt stratified random smapling mode that rat is divided into 5 groups, often group 14 also suitably adjusts and makes TC, HDL-C of each group of rat and original body mass balanced as far as possible.After starting test, except basal feed is according to except group, all the other are respectively organized equal high lipid food and feed and raise.Each rats in test groups per os gavage gives test solution, and two control group gavages give 5% starch solution, and gavage amount is 1.0ml/100g BW.Once a day, continuous 30 days, weigh once weekly, and according to body weight adjustment gavage amount.After test to fasting 16h during whole end, blood sampling measures serum TC, TG, HDL-C content.Serum TC, TG, HDL-C content.The mensuration of serum TC, TG and HDL-C content all uses enzyme reagent-end-point method.
1.6 experimental data processing: carry out statistical disposition with variance analysis.
1.7 results judge: in serum total cholesterol, monoglyceride, HDL-C three indexs, and serum total cholesterol and the triglycerides binomial index positive, can judge that given the test agent auxiliary lipid-lowering function animal experiment is positive.
2 result of the tests
2.1 samples are on the impact of rat body weight
Each group rat body weight no significant difference before test, body weight and the gain in weight of respectively organizing rat when process of the test each week and off-test compare, and difference does not all have significant (P>0.05), table
The growth of this sample bright to tested rat body weight does not have a significant effect, in table 1.
The changes of weight of front and back rat tested by table 1
Note: in table between each group comparing difference there are no significant (P>0.05).
2.2 samples are on the impact of serum total cholesterol TC content.
The tested rat experiment of table 2 is front and terminate TC content
Note: * * represents to have pole conspicuousness (P<0.01) with high fat control group comparing difference
Before experiment, each group Serum TC content is basically identical, the no significant difference (P<0.05) between each group.Experiment terminates the TC content of high fat control rats apparently higher than Basal control group, and difference has pole conspicuousness (P<0.01), shows that hyperlipidemia model is set up; At the end of experiment, the TC content of sample each dosage group is all lower than high fat control group, and the difference of each dosage group and negative control group all has pole conspicuousness (P<0.01), in table 2, show that this sample has the serum total cholesterol content effect reducing hyperlipidemia model rat.
2.3 samples are on the impact of serum glyceride (TG) content
Before experiment, respectively organize rat blood serum (TG) content basically identical, the no significant difference (P>0.05) between each group.The TG content of off-test height fat control rats is all higher than Basal control group, and difference has conspicuousness (P<0.01), shows that hyperlipidemia model is set up; During off-test, the TG content of sample each dosage group rat is all lower than high fat control group, and the difference of each dosage group and negative control group all has pole conspicuousness (P<0.01), in table 3, show that this sample has the effect reducing rat blood serum triglycerides.
The tested rat experiment of table 3 is front and terminate TG content
Note: * * represents to have pole conspicuousness (P<0.01) with high fat control group comparing difference
2.4 samples are on the impact of serum High Density Lipoprotein Cholesterol (HDL-C) content
The tested rat experiment of table 4 is front and terminate HDL-C content
Note: * and * * represents to have pole conspicuousness (P<0.05) and pole conspicuousness (P<0.01) with high fat control group comparing difference respectively
Before experiment, each group serum HDL-C level is basically identical, the no significant difference (P<0.05) between each group.The HDL-C content that experiment terminates high fat control rats is starkly lower than Basal control group, and difference has pole conspicuousness (P<0.01), shows that hyperlipidemia model is set up; During off-test, the HDL-C content of each dosage group is all higher than high fat control group, and the difference of each dosage group and negative control group all has conspicuousness (P<0.05 or P<0.01), in table 4, show that this sample has the effect of the serum High Density Lipoprotein Cholesterol content raising hyperlipidemia model rat.
3. result judges
Respectively with 175,350,700mg/kg BW(be equivalent to human body recommended amounts 5,10,20) blood fat lowering capsule of dosage is to the continuous gavage of hyperlipidemia model rat 30 days, serum total cholesterol (TC) and triglycerides (TG) content of rat can be reduced, improve the content of the serum High Density Lipoprotein Cholesterol (HDL-C) of rat, the body weight of rat is increased and has no significant effect.As can be seen here, this sample has auxiliary lipid-lowering function effect.
Embodiment 5
Health food hard shell capsules auxiliary lipid-lowering function of the present invention-human feeding trial report
1. materials and methods
1.1 samples: the auxiliary antilipemic capsule provided by the century-old healthy pharmaceutcal corporation, Ltd in Shaanxi, specification 0.35g/ intragranular is tolerant is sepia.Human body recommended amounts is adult (everyone) every day 2 times, each 3.
1.2 study subjects:
1.2.1 experimenter's inclusive criteria: the crowd of simple dyslipidemia, keeps usual diet, blood sampling 2 times in half a year.(1) twice serum total cholesterol (TC) is >=5.2mmol/L; (2) or twice serum glyceride (TG) >=1.65mmol/L.
1.2.2 Subject Exclusion Criteria: (1) age is under-18s or over-65s person; (2) gestation or women breast-feeding their children, to health food allergy sufferers: the serious diseases such as (3) merge intentionally, liver, kidney and hemopoietic system, cyclothymic patient; (4) take the article relevant with tested function in a short time, have influence on the judgement person to result; (5) do not meet inclusive criteria, not by the edible given the test agent of regulation, effect or data not umbra sound effect or security judgement person cannot be judged.
1.3 experimental design and grouping: adopt two kinds of control design between self and group.Requirement according to randomized double-blind is divided into groups.Connect experimenter's blood lipid level and be divided into test-meal group and control group at random, the principal element considering as far as possible affect result as age, sex, diet, carry out harmony and check, to ensure the comparativity between group.Often organize experimenter and be no less than 50 examples.
1.4 edible dosage and the times: test-meal group 2 times for each person every day; Each 3, control group adopts blank.Continuous Time of Administration is no less than 30 days, if desired can proper extension to 45 day.
1.5 key instruments, reagent and test environment require: electrocardiogram, X-ray examination machine, B ultrasonic scanner, Biochemical Analyzer, blood counting instrument, sphygmomanometer etc.
1.6 observation index:
1.6.1 safety indexes
1.6.1.1 ordinary circumstance: comprise the state of mind, sleep, diet, stool and urine etc., every day is by experimenter's record.
1.6.1.2 blood routine examination: apply full-automatic blood counting instrument and detect routine blood indexes, before experiment, tests and terminates respectively to do once.
1.6.1.3 blood pressure and liver, kidney, functional check: take blood pressure with blood pressure measuring, application automatic clinical chemistry analyzer measures blood Main Biochemical, and before experiment, experiment terminates respectively to do once.
1.6.1.4 Chest X-rays, electrocardiogram, Abdominal B type ultrasonography: before experiment starts, carry out a fluoroscopy of chest, electrocardiogram and Abdominal B type ultrasonography inspection.
1.6.2 efficiency index:
1.6.2.1 index: serum total cholesterol (TC) level and reduction percentage, triglycerides (TG) level and reduction percentage, HDL-C (TDL-C) level and ascensional range.
1.6.2.2 effect criterion: effectively: TC reduces >10%; TG reduces >15%; >0.104mmol/L is invalid in TDL-C rising: do not reach effective standard person.Observation serum total cholesterol (TC) is efficient, triglyceride (TG) is efficient, HDL-C (TDL-C) is efficient and total effective rate.The computational methods of total effective rate: each study subject only has index (TC, TG, a TDL-C) display effectively, namely counts efficiently individual quantity, efficiently individual quantity both obtained total effective rate divided by this group number.
1.7 data statistics: all own control data can adopt paired t-test, two groups of means compare and adopt into t inspection, the latter need carry out homogeneity test of variance, suitable variable transitions is carried out to the data of Non-Gaussian Distribution or heterogeneity of variance, after meeting normal state variance and be neat, carry out t inspection by the data of conversion; If translation data still can not meet the neat requirement of normal state variance, use t ' inspection or rank test instead, the neat side of variance but the logging data application rank test of the coefficient of variation too large (as CV>50%).Efficient and total effective rate adopts X
2inspection is tested.The total number of cases of four fold table is less than 40, or total number of cases is equal to or greater than 40 but occurs that theoretical value is equal to or less than 1, should use exact method method instead.
1.8 results judge: (1) serum total cholesterol and the triglycerides binomial index positive, HDL-C, not significantly lower than control group, can judge that this given the test agent has auxiliary lipid-lowering function effect.(2) an index positive in serum total cholesterol, triglycerides, two indexs, HDL-C, not significantly lower than control group, can judge that this given the test agent has auxiliary reduction serum total cholesterol or the effect of auxiliary reduction triglycerides.
2. result
2.1 ordinary circumstances: before test-meal, the age, mental status, sleep quality, diet situation etc. of test-meal group and control group crowd are basically identical, and the fluoroscopy of chest of two groups of crowds, electrocardiogram and Abdominal B type ultrasonography check result are showed no obvious abnormalities.Serum TC, TG, TDL-C there are no significant difference (P<0.05), in table 5
Two groups of crowd's serum TCs, TG, TDL-C comparision contents before table 5 test-meal
2.2 samples are on the impact of people with hyperlipidemia efficacy measures
After test-meal, serum TC and the TG content of test group crowd all have obvious reduction, self compare and with more all there is between control group pole significant difference (P<0.01); The serum HDL-C level of experimental group and control group compares, no significant difference (P>0.05); The total effective rate of test group auxiliary antilipemic is 74%, compares have pole significant difference (P<0.01) with 24% of control group, in table 6 ~ table 9, shows that this sample has and reduces the examination serum TC of trencherman, the effect of TG content.
Two groups of crowd's serum TC comparision contents before and after table 6 test-meal
Two groups of crowd's serum TG comparision contents before and after table 7 test-meal
Two groups of crowd serum T DL-C comparision contents before and after table 8 test-meal
Two groups of effective situations of crowd's auxiliary antilipemic after table 9 test-meal
2.3 samples are on the impact of safety indexes
2.3.1 sample is on the impact of blood pressure
The assay of two groups of crowd's blood pressures after table 10 test-meal
Before and after test-meal, the systolic pressure of experimental group and control group crowd and diastolic pressure, all in normal range (NR), in table 10, show that the blood pressure of this sample to experimenter has no adverse effects.
2.3.2 sample is on the impact of urine, feces routine
Before and after test-meal, the urine acid-base value of experimental group and control group crowd, transparency, color and urinary sediment microscopy no abnormality seen, Urine proteins is all unnegative, the stool colour of two groups of crowds, shape and microscopy are showed no exception, in table 11, table 12, show that the stool, urine routine of this sample to experimenter has no adverse effects.
The two groups of crowd's routine urinalysis assays in front and back tested by table 11
The assay of the two groups of crowd's stool routine examinations in front and back tested by table 12
2.3.3 sample is on the impact of routine blood test
Before and after test-meal, the erythrocyte number of experimental group and test-meal group crowd; Leukocyte count and content of hemoglobin, all in normal range (NR), in table 13, show that the routine blood indexes of this sample to experimenter has no adverse effects.
The assay of two groups of crowd's routine blood tests after table 13 test-meal
2.3.4 sample is on the impact of blood Main Biochemical.
The assay of two groups of crowd's blood parameters after table 14 test-meal
Before and after test-meal, the blood parameters check result of test group and control group crowd and all in normal range (NR), in table 14, show that the Liver and kidney function of this sample to experimenter has no adverse effects.
2.3.5 the bad reaction of sample, in experimentation test-meal sample person all do not occur feeling sick, the bad reaction such as flatulence, diarrhoea and allergy.
3. brief summary
3.1 meet this people with hyperlipidemia 100 example testing tested inclusion criteria (man 39 example, female 61 example), wherein experimental group 50 example takes blood fat lowering capsule of the present invention 30 days (2 times for each person every day continuously, each 3, specification is 350mg/ grain) after, result test-meal sample person TC, TG content obviously reduces, and test-meal sample person self compares and more all has conspicuousness (P<0.01) with control group; TDL-C content is without obviously changing (P>0.05), and total effective rate is 74%, has pole significant difference (P<0.01) with 24% of control group; Show that this sample has auxiliary lipid-lowering function effect.
Before and after 3.2 experiments, every check result such as erythrocyte number, leukocyte count, hemoglobin, stool and urine routine, total serum protein, albumin, glutamic-oxalacetic transaminease, glutamic-pyruvic transaminase, urea nitrogen, creatinine, blood sugar of test-meal sample sets crowd, all in normal range (NR), shows that this sample has no adverse effects to experimenter's health.
In 3.3 processs of the test, test-meal sample person is the bad reactions such as appearance is felt sick, flatulence, diarrhoea and allergy.
Claims (4)
1. a pharmaceutical composition for reducing blood lipid, it is made up of the bulk drug of following weight portion: dayflower 30-70 part, thizoma curculiginis 30-70 part, red sage root 30-70 part, ginkgo leaf 30-70 part, rhizoma alismatis 20-50 part, root of kudzu vine 20-50 part, honeycomb 5-15 part, gynostemma pentaphylla 10-30 part.
2. the pharmaceutical composition of reducing blood lipid according to claim 1, it is characterized in that, the weight portion of each bulk drug is respectively: dayflower 40-60 part, thizoma curculiginis 40-60 part, red sage root 40-60 part, ginkgo leaf 40-60 part, rhizoma alismatis 30-40 part, root of kudzu vine 30-40 part, honeycomb 8-12 part, gynostemma pentaphylla 15-25 part.
3. the pharmaceutical composition of reducing blood lipid according to claim 1 and 2, it is characterized in that, the weight portion of each bulk drug is respectively: dayflower 50 parts, thizoma curculiginis 50 parts, the red sage root 50 parts, ginkgo leaf 50 parts, rhizoma alismatis 35 parts, the root of kudzu vine 35 parts, 10 parts, honeycomb, gynostemma pentaphylla 20 parts.
4. a preparation method for the pharmaceutical composition of reducing blood lipid described in any one of claim 1-3, is characterized in that comprising the following steps: by the root of kudzu vine pulverize, cross 100 mesh sieves, every prescription collect 50g fine powder (
60co radiation, dosage < 5ky), all the other meal are for extraction; The red sage root, ginkgo leaf, rhizoma alismatis, the root of kudzu vine, gynostemma pentaphylla, dayflower, thizoma curculiginis, honeycomb 80% alcohol reflux extract 2 times, first time adds 10 times amount solvent extraction 2h, second time adds 8 times amount solvent extraction 1.5h, merges twice filtrate (the another device of the dregs of a decoction is preserved), decompression (-0.065 ~-0.075Mpa; 60 DEG C) concentrated, reclaim ethanolic solution and be concentrated into relative density 1.32 ~ 1.35(60 DEG C) medicinal extract 1 for subsequent use; The above-mentioned dregs of a decoction add 8 times amount soak by water 1 time, and the time, 1.5h considered, filtrate decompression (-0.065 ~-0.075Mpa; 60 DEG C) to be concentrated into relative density be 1.32 ~ 1.35(60 DEG C) medicinal extract 2 for subsequent use; Medicinal extract 1 and medicinal extract 2, root of kudzu vine fine powder are mixed, dry, pulverize 80 mesh sieves with less than 65 DEG C reduce pressure (-0.075 ~-0.085Mpa); Above-mentioned fine powder 85% appropriate amount of ethanol makes softwood, 20 mesh sieves granulate less than 60 DEG C dry, the whole grain of 16 mesh sieve, loads No. 0 capsule and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310331251.3A CN104336596A (en) | 2013-08-01 | 2013-08-01 | Medicine composition capable of lowering blood lipid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310331251.3A CN104336596A (en) | 2013-08-01 | 2013-08-01 | Medicine composition capable of lowering blood lipid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104336596A true CN104336596A (en) | 2015-02-11 |
Family
ID=52493670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310331251.3A Pending CN104336596A (en) | 2013-08-01 | 2013-08-01 | Medicine composition capable of lowering blood lipid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104336596A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031045A (en) * | 2015-09-15 | 2015-11-11 | 曾盛钊 | Heart protecting and liver nourishing tea |
| CN106107987A (en) * | 2016-07-02 | 2016-11-16 | 马玉玲 | A kind of health food with immunomodulating, cosmetology function and preparation method thereof |
| WO2018072276A1 (en) * | 2016-10-19 | 2018-04-26 | 广西中医药大学 | Health-care food and preparation method therefor |
| CN109528827A (en) * | 2019-01-09 | 2019-03-29 | 武汉百理王生物工程有限公司 | A kind of promoting blood circulation, reducing blood lipid, the pharmaceutical composition of auxiliary adjustment cardiovascular and cerebrovascular disease and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1685913A (en) * | 2005-04-28 | 2005-10-26 | 郭博 | Body building tea bag and its preparation method |
| KR20060023762A (en) * | 2004-09-10 | 2006-03-15 | 롯데제과주식회사 | The extract of korean fermented soybean with inhibitory effect on hyperlipemia and platelet aggregation, and their composition |
| CN1883623A (en) * | 2006-05-18 | 2006-12-27 | 武汉理工大学 | A blood fat-decreasing compound Chinese medicine and preparation method thereof |
| CN101239112A (en) * | 2007-02-09 | 2008-08-13 | 上海中医药大学 | Chinese medicinal composition for regulating blood fat and preparation thereof |
-
2013
- 2013-08-01 CN CN201310331251.3A patent/CN104336596A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060023762A (en) * | 2004-09-10 | 2006-03-15 | 롯데제과주식회사 | The extract of korean fermented soybean with inhibitory effect on hyperlipemia and platelet aggregation, and their composition |
| CN1685913A (en) * | 2005-04-28 | 2005-10-26 | 郭博 | Body building tea bag and its preparation method |
| CN1883623A (en) * | 2006-05-18 | 2006-12-27 | 武汉理工大学 | A blood fat-decreasing compound Chinese medicine and preparation method thereof |
| CN101239112A (en) * | 2007-02-09 | 2008-08-13 | 上海中医药大学 | Chinese medicinal composition for regulating blood fat and preparation thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王垣芳，等: "鸭跖草对高血脂血症小鼠脂代谢及抗氧化能力的影响", 《中国实验方剂学杂志》, vol. 18, no. 16, 31 August 2012 (2012-08-31), pages 273 - 277 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031045A (en) * | 2015-09-15 | 2015-11-11 | 曾盛钊 | Heart protecting and liver nourishing tea |
| CN106107987A (en) * | 2016-07-02 | 2016-11-16 | 马玉玲 | A kind of health food with immunomodulating, cosmetology function and preparation method thereof |
| WO2018072276A1 (en) * | 2016-10-19 | 2018-04-26 | 广西中医药大学 | Health-care food and preparation method therefor |
| CN109528827A (en) * | 2019-01-09 | 2019-03-29 | 武汉百理王生物工程有限公司 | A kind of promoting blood circulation, reducing blood lipid, the pharmaceutical composition of auxiliary adjustment cardiovascular and cerebrovascular disease and preparation method thereof |
| CN109528827B (en) * | 2019-01-09 | 2021-11-12 | 武汉百理王生物工程有限公司 | Pharmaceutical composition and preparation for promoting blood circulation, removing blood stasis and reducing blood fat and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102187887B (en) | Sandwich biscuit with functions of losing weight and regulating blood sugar and production method thereof | |
| CN101095751B (en) | Medicinal composition having functions of removing chloasma and improving nutritional anemia and method for preparing the same | |
| WO2015172608A1 (en) | Capsule for assisting in reducing blood fat and preparation method therefor | |
| CN101822749A (en) | Medicinal preparation for curing hypertension and hyperlipaemia and preparation method thereof | |
| CN104187678B (en) | A kind of health composition of reducing blood lipid and production method thereof | |
| CN104336596A (en) | Medicine composition capable of lowering blood lipid and preparation method thereof | |
| CN107048381A (en) | A kind of health food for improving sleep and preparation method thereof | |
| CN100579545C (en) | Health-care wine with sleeping improving and beauty functions and its preparing process | |
| CN105055855B (en) | With Chinese medicine composition for improving sleep, strengthen immunity effect and its preparation method and application | |
| CN101356975B (en) | Health food capable of increasing human immunity and promoting intelligence and strengthening brain and preparation method thereof | |
| CN105941562A (en) | Health-care biscuit for preventing and treating hyperglycemia | |
| CN109771578A (en) | The composition for preventing and treating diabetes and complication | |
| CN108888682A (en) | A kind of improving eyesight eyeshield composition | |
| CN100428951C (en) | Yuanhe tablet and process for preparing the same | |
| CN101829272B (en) | Traditional Chinese medicine composition for treating diabetes mellitus and preparation method thereof | |
| CN104256618B (en) | A kind of hypoglycemic food, health products or pharmaceutical composition | |
| CN102266428A (en) | Anti-ageing Chinese medicinal composition and preparation method and application thereof | |
| CN106177176B (en) | A kind of Halth-care composition and its preparation method and application | |
| CN103735603A (en) | Compound lipid-decreasing soft capsule and preparation method thereof | |
| CN100488519C (en) | Medicine for treating dysmenorrhea and its preparing method | |
| CN109663131A (en) | The composition of relax bowel and defecation | |
| CN103027963B (en) | Health care composition for relaxing bowels and improving organism immunity and preparation method | |
| CN103520401B (en) | A kind of Traditional Chinese medicine health-preserving preparation with auxiliary lipid-lowering function | |
| CN102552643A (en) | Combination with blood fat reducing function and application of same | |
| CN103006921A (en) | Composition having health care effects on cardiovascular and cerebrovascular anoxia and on toxicity of excess oxidation to human body, and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150211 |